GlassScriptPhysician profile
Austin Osemeka
NPI 1699897249
$32,006.88
in general payments reported to CMS, 2019-2025
35 companies · $1,373 in 2025
The $1,373 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,537 · 2020: $5,747 · 2021: $4,518 · 2022: $12K · 2023: $2,791 · 2024: $782 · 2025: $1,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,173 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,673 · Education: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,173.41 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,672.50 |
| Education | $100.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $8,193.03 | 2019-2025 | Epclusa |
| E.R. Squibb & Sons, L.L.C. | $7,488.86 | 2021-2023 | Zeposia |
| Celgene Corporation | $6,061.32 | 2021-2024 | Zeposia |
| Allergan, INC. | $4,497.47 | 2019-2020 | |
| Abbvie INC. | $1,440.40 | 2019-2025 | |
| Janssen Biotech, INC. | $655.03 | 2019-2025 | Tremfya, Stelara, Remicade |
| Madrigal Pharmaceuticals | $482.14 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $348.85 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $309.52 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $256.30 | 2019-2023 | Gattex |
| Janssen Scientific Affairs, LLC | $253.13 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $195.10 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $192.99 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $187.65 | 2023-2025 | Voquezna |
| Qol Medical, LLC | $158.59 | 2020-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuraxis, INC. | $141.49 | 2025 | |
| Amgen INC. | $139.82 | 2024 | Krystexxa |
| Viiv Healthcare Company | $125.21 | 2023 | |
| Janssen Pharmaceuticals, INC | $117.48 | 2019-2025 | |
| Pfizer INC. | $115.93 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $97.98 | 2021-2023 | Dificid |
| Genzyme Corporation | $87.59 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $66.55 | 2020-2023 | Linzess |
| Shionogi INC | $59.13 | 2019-2020 | |
| Sandoz INC. | $58.15 | 2024-2025 | Hyrimoz |
| Ardelyx, INC. | $57.05 | 2022-2025 | Ibsrela |
| Organon LLC | $47.56 | 2023-2025 | Hadlima |
| Ipsen Biopharmaceuticals, INC | $36.54 | 2024-2025 | Iqirvo |
| Mirum Pharmaceuticals, INC. | $23.55 | 2022 | |
| Vivus LLC | $23.11 | 2021 | |
| Ucb, INC. | $23.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $20.00 | 2022 | |
| Daiichi Sankyo INC. | $16.13 | 2019 | |
| Ambu INC. | $15.84 | 2021 | |
| Shire North American Group INC | $14.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Austin Osemeka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.